152 related articles for article (PubMed ID: 11739187)
1. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells.
Schernthaner GH; Jordan JH; Ghannadan M; Agis H; Bevec D; Nuñez R; Escribano L; Majdic O; Willheim M; Worda C; Printz D; Fritsch G; Lechner K; Valent P
Blood; 2001 Dec; 98(13):3784-92. PubMed ID: 11739187
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
[TBL] [Abstract][Full Text] [Related]
3. T cell receptor-independent CD2 signal transduction in FcR+ cells.
Arulanandam AR; Koyasu S; Reinherz EL
J Exp Med; 1991 Apr; 173(4):859-68. PubMed ID: 1706751
[TBL] [Abstract][Full Text] [Related]
4. Human leukaemic (HMC-1) and normal skin mast cells express beta 2-integrins: characterization of beta 2-integrins and ICAM-1 on HMC-1 cells.
Weber S; Babina M; Feller G; Henz BM
Scand J Immunol; 1997 May; 45(5):471-81. PubMed ID: 9160089
[TBL] [Abstract][Full Text] [Related]
5. Expression of lymphoid-associated antigens in mast cells: report of a case of systemic mast cell disease.
Escribano L; Orfao A; Villarrubia J; Cerveró C; Velasco JL; Martín F; San Miguel JF; Navarro JL
Br J Haematol; 1995 Dec; 91(4):941-3. PubMed ID: 8547146
[TBL] [Abstract][Full Text] [Related]
6. Sheep erythrocyte rosetting induces multiple alterations in T lymphocyte function: inhibition of T cell receptor activity and stimulation of T11/CD2.
Breitmeyer JB; Faustman DL
Cell Immunol; 1989 Oct; 123(1):118-33. PubMed ID: 2570643
[TBL] [Abstract][Full Text] [Related]
7. 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand.
Ghanim V; Herrmann H; Heller G; Peter B; Hadzijusufovic E; Blatt K; Schuch K; Cerny-Reiterer S; Mirkina I; Karlic H; Pickl WF; Zöchbauer-Müller S; Valent P
Blood; 2012 May; 119(18):4242-52. PubMed ID: 22438247
[TBL] [Abstract][Full Text] [Related]
8. Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils.
Krauth MT; Böhm A; Agis H; Sonneck K; Samorapoompichit P; Florian S; Sotlar K; Valent P
Exp Hematol; 2007 Jan; 35(1):108-16. PubMed ID: 17198879
[TBL] [Abstract][Full Text] [Related]
9. Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia.
Escribano L; Orfao A; Villarrubia J; Martín F; Madruga JI; Cuevas M; Velasco JL; Rios A; San Miguel JF
Cytometry; 1997 Apr; 30(2):98-102. PubMed ID: 9149916
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
[TBL] [Abstract][Full Text] [Related]
11. Rosetting of activated human T lymphocytes with autologous erythrocytes. Definition of the receptor and ligand molecules as CD2 and lymphocyte function-associated antigen 3 (LFA-3).
Plunkett ML; Sanders ME; Selvaraj P; Dustin ML; Springer TA
J Exp Med; 1987 Mar; 165(3):664-76. PubMed ID: 3102675
[TBL] [Abstract][Full Text] [Related]
12. The transcriptome of the human mast cell leukemia cells HMC-1.2: an approach to identify specific changes in the gene expression profile in KitD816V systemic mastocytosis.
Haenisch B; Herms S; Molderings GJ
Immunol Res; 2013 May; 56(1):155-62. PubMed ID: 23504229
[TBL] [Abstract][Full Text] [Related]
13. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis.
Valent P; Sperr WR; Samorapoompichit P; Geissler K; Lechner K; Horny HP; Bennett JM
Leuk Res; 2001 Jul; 25(7):595-602. PubMed ID: 11377685
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders.
Sánchez-Muñoz L; Teodósio C; Morgado JM; Escribano L
Methods Cell Biol; 2011; 103():333-59. PubMed ID: 21722810
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms.
Valent P; Sotlar K; Horny HP
Leuk Lymphoma; 2011 May; 52(5):740-4. PubMed ID: 21261503
[TBL] [Abstract][Full Text] [Related]
16. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
Santos DD; Hatjiharissi E; Tournilhac O; Chemaly MZ; Leleu X; Xu L; Patterson C; Branagan AR; Manning RJ; Ho AW; Hunter ZR; Dimmock EA; Kutok JL; Churchill WH; Castells MC; Tai YT; Anderson KC; Treon SP
Clin Lymphoma Myeloma; 2006 May; 6(6):478-83. PubMed ID: 16796779
[TBL] [Abstract][Full Text] [Related]
17. RasGRP4, a new mast cell-restricted Ras guanine nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. Identification of defective variants of this signaling protein in asthma, mastocytosis, and mast cell leukemia patients and demonstration of the importance of RasGRP4 in mast cell development and function.
Yang Y; Li L; Wong GW; Krilis SA; Madhusudhan MS; Sali A; Stevens RL
J Biol Chem; 2002 Jul; 277(28):25756-74. PubMed ID: 11956218
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion.
Morgado JM; Sánchez-Muñoz L; Teodósio CG; Jara-Acevedo M; Alvarez-Twose I; Matito A; Fernández-Nuñez E; García-Montero A; Orfao A; Escribano L
Mod Pathol; 2012 Apr; 25(4):516-21. PubMed ID: 22222639
[TBL] [Abstract][Full Text] [Related]
19. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
20. Expression of cell surface antigens on mast cells: mast cell phenotyping.
Hauswirth AW; Florian S; Schernthaner GH; Krauth MT; Sonneck K; Sperr WR; Valent P
Methods Mol Biol; 2006; 315():77-90. PubMed ID: 16110150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
